HomeBHM0 • FRA
add
BACHEM HOLDING AG
Nakaraang pagsara
€72.40
Sakop ng araw
€72.90 - €72.90
Sakop ng taon
€51.25 - €81.50
Market cap
5.16B CHF
Average na Volume
27.00
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (CHF) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 191.04M | 4.70% |
Gastos sa pagpapatakbo | 4.65M | -61.22% |
Net na kita | 49.35M | 17.36% |
Net profit margin | 25.83 | 12.11% |
Kita sa bawat share | — | — |
EBITDA | 63.83M | 9.45% |
Aktuwal na % ng binabayarang buwis | 1.53% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (CHF) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 30.99M | -67.45% |
Kabuuang asset | 2.11B | 9.66% |
Kabuuang sagutin | 650.41M | 22.28% |
Kabuuang equity | 1.46B | — |
Natitirang share | 74.94M | — |
Presyo para makapag-book | 3.72 | — |
Return on assets | 5.95% | — |
Return on capital | 8.26% | — |
Cash Flow
Net change in cash
| (CHF) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 49.35M | 17.36% |
Cash mula sa mga operasyon | 92.80M | 220.31% |
Cash mula sa pag-invest | -89.05M | -624.68% |
Cash mula sa financing | -2.81M | -391.01% |
Net change in cash | 923.00K | -94.31% |
Malayang cash flow | -43.10M | -92.30% |
Tungkol
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients. The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.
The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz, Vista and Torrance, and St Helens, as well as a sales and distribution site in Tokyo.
Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies.
In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States.
At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million. Wikipedia
CEO
Itinatag
1971
Website
Mga Empleyado
2,363